Difference between revisions of "Hepatoblastoma"
Jump to navigation
Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#4a1486"|'''Section editor''' |- |s...") |
|||
| Line 54: | Line 54: | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
| + | |- | ||
| + | |[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.14.2665 Ortega et al. 2000] | ||
| + | | style="background-color:#1a9851" |Phase III (E) | ||
| + | |Cisplatin, 5-FU, Vincristine | ||
| + | | style="background-color:#ffffbf" |Seems not superior | ||
|- | |- | ||
|[https://www.nejm.org/doi/10.1056/NEJMoa0810613 Perilongo et al. 2009 (SIOPEL 3)] | |[https://www.nejm.org/doi/10.1056/NEJMoa0810613 Perilongo et al. 2009 (SIOPEL 3)] | ||
| Line 66: | Line 71: | ||
===References=== | ===References=== | ||
| + | # Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000 Jul;18(14):2665-75. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.14.2665 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10894865 PubMed] | ||
# '''SIOPEL 3:''' Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. [https://www.nejm.org/doi/10.1056/NEJMoa0810613 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19846851 PubMed] | # '''SIOPEL 3:''' Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. [https://www.nejm.org/doi/10.1056/NEJMoa0810613 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19846851 PubMed] | ||
Revision as of 03:08, 11 December 2018
| Section editor | |
|---|---|
 |
Wayne H. Liang, MD, MS Birmingham, AL Twitter: WayneLiangMD |
7 regimens on this page
7 variants on this page
|
All lines of therapy
Cisplatin monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Perilongo et al. 2009 (SIOPEL 3) | Phase III (E) | Cisplatin & Doxorubicin | Non-inferior complete resection rate |
Chemotherapy
References
- SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed
Cisplatin & Doxorubicin
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Ortega et al. 2000 | Phase III (E) | Cisplatin, 5-FU, Vincristine | Seems not superior |
| Perilongo et al. 2009 (SIOPEL 3) | Phase III (C) | Cisplatin | Non-inferior complete resection rate |
Chemotherapy
References
- Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000 Jul;18(14):2665-75. link to original article PubMed
- SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed